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BACKGROUND: Ovarian cancer is the 8th most prevalent cancer in women in the world. Current biomarker prognosis for ovarian cancer has 
numerous limitations, thus new biomarkers are needed. 
MicroRNAs (miRs) are considered as potential biomarkers 
in ovarian cancer as they are stable in blood. One candidate 
is miR-200c, the main regulator in epithelial transition to 
the mesenchyme. The aim of this study is to determine the 
role of miR-200c as prognostic biomarker for epithelial 
ovarian cancer (EOC).
METHODS: This is a prospective cohort study conducted 
at Dr. Sardjito Central General Hospital in Yogyakarta 
from September 2015 to July 2018. Sampling was done 
using consecutive sampling method. Forty plasma samples 
of EOC subjects were included in this study. miR-200c 
expression was quantified using Reverse Transcriptase 
Quantitative Quantitative Polymerase Chain Reaction (RT-
qPCR) with miR-16 as the reference gene.
RESULTS: The expression of miR-200c was significantly 
higher in the group of subjects with preoperative CA-125 
levels >500 U/mL (p=0.009) than the group of subjects 
with preoperative CA-125 levels <500 U/mL. Subjects with 
higher miR-200c expression had lower survival rate than 
subjects with lower miR-200c expression, although not 
statistically significant. 
CONCLUSION: The miR-200c could be a promising 
biomarker  for  EOC.  Further  studies  with  larger  sample 
sizes  are  needed  to  clarify  the  prognostic  value  of  miR-
200c. 
KEYWORDS: miR-200c, epithelial ovarian cancer, 
prognosis, overall survival
Indones Biomed J. 2019; 11(3): 267-72 
Abstract
Introduction
Ovarian cancer is the third most prevalent cancer in women in 
Indonesia. Usually diagnosed in stage III-IV, ovarian cancer 
patient survival is generally low.(1) In a study performed 
at Dr. Cipto Mangunkusumo Central General Hospital, the 
5-year survival rate of epithelial ovarian cancer patients was 
54.8%.(2) There is barely any difference between incidence 
and mortality rate of ovarian cancer in developed and 
developing countries due to the fact that in all countries, 70% 
of patients were diagnosed in advanced stage.(3) Although 
new developments in detection and treatment of ovarian 
cancer are continually appearing, ovarian cancer is still the 
deadliest cancer in women. Determination of prognosis in 
ovarian cancer patients is an essential part of evaluation and 
therapy. Efforts to identify prognostic factors in epithelial 
ovarian cancer (EOC) continue to be sought in further 
research areas, including tumor characteristics, surgery, 
genetic patterns, immunological actors, and proteomic 
patterns.
  Over the past ten years, scientific developments have 
changed the traditional concept of ovarian cancer. Ovarian 
cancer is currently not identified as a single disease, but rather 
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diagnosed as a group of diseases with distinct morphologies 
and behaviors. About 80% of patients who have tumor 
residual disease after surgery and receive platinum-
based combination chemotherapy, will have a median of 
18-month  disease-free  survival  rate.(4)  Identification  of 
factors related to  disease  aggressiveness  can  direct  the 
development of  new  biomarkers  and  identification  of 
targeted  therapies  that would greatly ameliorate the burden 
of this disease.(5)
 MicroRNAs (miRs) are short RNA sequences which 
do not encode proteins but are the main expression regulators 
of various genes by acting on base pairs of 3'UTR mRNA 
targets that determine mRNA degradation or translation 
inhibition. The miRs are involved in the process of 
carcinogenesis, cell cycle, apoptosis, proliferation, invasion, 
metastasis, and chemoresistance. Their dysregulation is 
related with initiation and development of cancer in human, 
including ovarian cancer. miRs can act as onco-miR or as a 
tumor suppressor-miR. miRs are stable in blood circulation 
so they have potential as non-invasive biomarkers. Research 
on the role of miRs in tumorigenesis can provide a new 
paradigm for understanding ovarian cancer. The pattern of 
miR expression in primary tissue, circulation, and effusion 
fluid of ovarian cancer patients is not  the  only  a  potential 
marker  in  the  detection and screening of non-invasive 
ovarian cancer, but can also be associated with survival, 
prognosis, and predictions of recurrence.(6)
 miR-200c, a member of the miR-200 family, 
influences various types of cancer, including ovarian cancer. 
The miR-200c has been reported to play a role in epithelial-
mesenchymal transition (EMT), cancer stem cells (CSC), 
differentiation, modulation of cell division, apoptosis, 
and chemoresistance.(7) In this study, miR-200c in blood 
plasma is studied  as  a potential biomarker in determining 
prognosis in EOC.
Methods
Subject Recruitment
A prospective cohort study was conducted at Dr. Sardjito 
Central General Hospital in Yogyakarta from September 
2015 to July 2018. Ethical clearance was granted from 
the Faculty of Medicine Universitas Gadjah Mada (KE/
FK/1085/EC/2015). Sixty-two subjects were recruited with 
consecutive sampling method. Subjects who suffer EOC, 
confirmed with clinical and histopathological examinations, 
were included, whereas subjects who had history of benign 
tumor and other cancer, were excluded. The EOC stage 
was classified based on The International Federation of 
Gynecology and Obstetrics/Fédération Internationale de 
Gynécologie et d'Obstétrique (FIGO).
Sample Collection
Pre-operative 5 mL peripheral venous blood was drawn in 
an ethylenediaminetetraacetic acid (EDTA) tube. Half of the 
blood was used to measure CA-125 level at Laboratory of 
Clinical Pathology, Dr. Sardjito Central General Hospital. 
And the other half was processed to get plasma for 
further analysis using Reverse Transcriptase Quantitative 
Polymerase Chain Reaction (RT-qPCR). After surgery, 
tumor was collected, prepared for hematoxylin-eosin 
staining and examined by pathologists.
RT-qPCR
RNA was isolated from plasma using miRCURY RNA 
Isolation Kit-Biofluids (Exiqon, Vedbaek, Denmark). Then 
total cDNA was prepared immediately from RNA using a 
Universal cDNA Synthesis kit (Exiqon). The qPCR was 
performed  using  miRCURY  LNA  Universal  RT microRNA 
(Exiqon) with hsa-miR-16-5p LNA (Exiqon) and hsa-miR-
200c  LNA primer  sets  (Exiqon). PCR was set for 40 
cycles. miR-16  was  used  as  the  internal  control.  Analysis 
was  carried  out  using  GenEx 6 software to get results in 
the form of fold change and to measure the expressions of 
miR-200c. Data was processed using the CFX Manager 96 
Biorad program to obtain the quantification cycle (Cq). 
Survival Rate and Cox Regression 
Analysis of survival rate and Cox regression was done 
using SPSS version 23.0 (IBM Corp, New York, USA). 
Determination of high and low miR expressions was 
conducted using software R2: Genomic Analysis and 
Visualization Platform.
From 62 subjects, 40 subjects were included in the study 
based on the inclusion and exclusion criteria. Most subjects 
were >50 years old (52.5%) and had ≥1 parity (72.5%), 
early stage (57.5%), histopathology type I (60%), <1 cm 
residual tumor (65%), and <500 U/mL pre-operative CA-
125 (57.5%) (Table 1).
The miR-200c Expression of EOC Subjects
The expression of the miR-200c was shown in fold change 
compared to miR-16. The miR-200c fold changes (Figure 
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n (%)
Age (years) ≤50 19 (47.5%)
>50 21 (52.5%)
Parity Nulliparity 11 (27.5%)
Parity ≥1 29 (72.5%)
EOC Stage
Early Stage (Stage I-II) I 19 (47.5%)
II 4 (10%)
Late Stage III-IV III 13 (32.5%)
IV 4 (10%)
Histopathology 
Type I Low-grade serous 4 (10%)
Clear cell 5 (12.5%)
Mucinous carcinoma 14 (35%)
Malignant Brenner tumor 1 (2.5%)
Type II High-grade serous 12 (30%)
High-grade endometrioid 2 (5%)
Undifferentiated carcinoma 1 (2.5%)
Carcinosarcoma 1 (2.5%)
<1 26 (65%)
≥1 14 (35%)
<500 23 (57.5%)
≥500 17 (42.5%)
Category
Residual Tumor After Surgery (cm)
Pre-operative CA-125 Level (U/mL)
Table 1. EOC subject characteristics.
1)  and  DCq  (Table 2)  were  analyzed  in  different  age, 
parity,  EOC  stage,  histopathology  type,  residual  tumor, 
and  CA-125  levels.  A  significant  difference  in  mean  of 
miR-200c  DCq  between  the  group  of  pre-operative <500 
U/mL and ≥500 U/mL CA-125 was observed (p=0.009) 
(Table 2).
miR-200c and Overall Survival of EOC Subjects
The  overall  survival  was  recorded  for  3  months 
starting from the date of surgery. Among 40 subjects who 
were included in the study, 15 subjects died (35%) and 25 
people survived (65%). Using R2 Genomic Analysis and 
Visualization Platform, low and high miR-200c groups were 
classified and then analyzed using the Kaplan-Meier method 
for overall survival. Using log-rank test, low expression of 
miR-200c was shown to be associated with higher overall 
survival, although not statistically significant (Table 3, 
Figure 2).
Discussion
Most of the EOC subjects in this study were in the stage 
I-II (57.5%), which is different from the majority of studies 
whose subjects were 60-70% in the stage III-IV.(1) This 
might be related with the fact that the majority of the subjects 
of this study were having histopathology type I (60%). The 
results of this study are not much different from studies 
which found that the most common histopathology type was 
serous carcinoma, followed by mucinous and endometrioid 
carcinoma.(8,9) The EOC type I grows slowly, usually in 
stage I-II, rarely has a p53 mutation and tends to be resistant 
to platinum-based chemotherapy.(10) 
 The miR-200c expression of the group with 
preoperative CA-125 level >500 U/mL was significantly 
higher (p=0.009) than the group with <500 U/mL. Although 
not significant, miR-200c expression was higher in the 
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Figure 1. miR-200c fold change of EOC subjects. The expression of miR-200c gene was shown in fold change compared to miR-16. 
miR-200c fold changes of EOC subjects were grouped in different age (A), parity (B), EOC stage (C), histopathology type (D), residual 
tumor (E) and preoperative CA-125 level (F). 
EOC histopathology type II than in the type I. miR-200c 
expressions was also higher in EOC Stage I-II than Stage 
III-IV. The increase of miR-200c expression in this study 
showed a tendency towards severity of EOC. This is in 
agreement with the previous study, which found a significant 
difference in the miR-200c expression between EOC stage 
III-IV and healthy controls.(11)
Some studies stated that higher expression level of the 
miR-200 family was associated with decrease in patient’s 
survival, while in other studies the opposite effect of high 
miR-200 expression has been reported. The exact reason 
underlying these contradictory findings is still not clear. 
One report shows that miR-200c can act as a suppressor or 
trigger for aggressive phenotypes, depending on the location 
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 Category Mean of miR-200c ∆Cq p -value
Age (years)
<50 0.01±1.18
>50 0.20±2.63
Parity
Nulliparity 0.01±2.07
Parity ≥1 1.19±2.00
EOC Stage
Stage I-II 0.01±1.37
Stage III-IV 1.36±2.74
Histopathology
Type I 0.01±1.32
Type II 1.12±2.76
Residual Tumor After Surgery (cm)
<1 0.01±2.11
>1 0.97±1.99
Pre-operative CA-125 Level (U/mL)
<500 0.01±1.56 0.009
>500 1.67±2.34
0.16
0.37
0.09
0.76
0.1
Table 2. The miR-200c DCq of EOC subjects.
Level of miR-200c 
Expression n Mortality
Hazard Ratio 
(HR)
Confidence 
Interval (CI) 95%    p -value
Low 11 2 1
High 29 13 1.908
0.1670.638-12.543
Table 3. miR-200c expressions and overall survival of EOC subjects.
of the Human antigen R (HuR).(12)  In current study, after 
bivariate analysis using log-rank test and Kaplan-Meier 
curve, it was found that high miR-200c expression had lower 
overall EOC patient survival, but not statistically significant. 
This result suggests a possible oncomiR role of miR-200c 
in EOC. The finding of miR-200c as an oncomiR has been 
reported in serous ovarian cancer, the high expression of 
miR-200c had a worse median overall survival compared to 
the one of low miR-200c expression.(13)
 The relationship between the high expression of 
the miR-200 family and the prognosis of cancer is still 
controversial. It has been shown in a meta-analysis report 
that  high  expression  of  the  miR-200  family  in  various 
tumors was associated with a low overall survival. The 
expression of the miR-200 family is associated with a poor 
prognosis of various types of cancer, implying the potential 
of the family miR-200 family for cancer prognosis in 
clinical practice.(14) 
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Figure 2. Survival rate of subjects with different 
miR-200c expression levels.
Conclusion
The miR-200c expression is correlated with the severity in 
EOC. Higher expression of miR-200c correlate with worse 
overall survival, although not statistically significant. miR-
200c could be a promising biomarker for EOC. Further 
studies with larger sample sizes are needed to clarify the 
prognostic value of miR-200c.
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